Literature DB >> 11444478

Faecal elastase-1: lyophilization of stool samples prevents false low results in diarrhoea.

B Fischer1, S Hoh, M Wehler, E G Hahn, H T Schneider.   

Abstract

BACKGROUND: In patients with diarrhoea, faecal elastase-1 is used to detect exocrine pancreatic insufficiency. Diarrhoea is defined as >85% stool water content.
METHODS: We analysed elastase-1 in 519 stool samples from 310 patients unprocessed as well as after lyophilization in a standard laboratory lyophilizator. Stool water content was calculated by weight difference before and after lyophilization.
RESULTS: 151 stool samples were classified as 'diarrhoea' (mean stool water content 88.8%); all others had a mean water content of 75.4%. In the 'diarrhoea' samples, elastase-1 levels were considerably higher after lyophilization--with a calculated normal water content of 75% (606 +/- 359 microg/g, mean +/- s)--compared to measurement when unprocessed (279 +/- 151 microg/g; P < 0.0001). In 16 of the 151 cases (11%), the abnormally low elastase-1 level below 200 microg/g found in unprocessed stools proved normal (>200 microg/g) after lyophilization and correction for stool water content.
CONCLUSION: Diarrhoea can result in falsely decreased elastase-1 levels in a number of patients with non-pancreatogenic diarrhoea. Lyophilization is a simple measure by which to determine elastase-1 independently of stool water content. Lyophilization of stool samples can therefore help to prevent wrong positive elastase-1 test results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444478     DOI: 10.1080/003655201300192058

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  17 in total

1.  Fecal elastase 1 is not the indirect pancreatic function test we have been waiting for.

Authors:  P G Lankisch; I Schmidt
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation?

Authors:  Kate E Evans; John S Leeds; Stephen Morley; David S Sanders
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

3.  How to manage: patient with a low faecal elastase.

Authors:  Kwan Wai Lam; John Leeds
Journal:  Frontline Gastroenterol       Date:  2019-11-15

4.  Identification of risk factors for pancreatic exocrine insufficiency after pancreaticoduodenectomy using a 13C-labeled mixed triglyceride breath test.

Authors:  Seiko Hirono; Yoshiaki Murakami; Masaji Tani; Manabu Kawai; Ken-ichi Okada; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naoya Nakagawa; Naru Kondo; Hiroki Yamaue
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

5.  Fecal pancreatic elastase: a reproducible marker for severe exocrine pancreatic insufficiency.

Authors:  Satoru Naruse; Hiroshi Ishiguro; Shigeru B H Ko; Toshiyuki Yoshikawa; Takeshi Yamamoto; Akiko Yamamoto; Sachiko Futakuchi; Hidemi Goto; Yukio Saito; Susumu Takahashi
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

6.  A novel role for the metabotropic glutamate receptor-7: modulation of faecal water content and colonic electrolyte transport in the mouse.

Authors:  M Julio-Pieper; N P Hyland; J A Bravo; T G Dinan; J F Cryan
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 7.  The role of fecal elastase-1 in detecting exocrine pancreatic disease.

Authors:  John S Leeds; Kofi Oppong; David S Sanders
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-05-31       Impact factor: 46.802

8.  Diagnosis of Exocrine Pancreatic Insufficiency.

Authors:  Phil A Hart; Darwin L Conwell
Journal:  Curr Treat Options Gastroenterol       Date:  2015-09

9.  Now that fecal elastase is available in the United States, should clinicians start using it?

Authors:  Paul G Lankisch
Journal:  Curr Gastroenterol Rep       Date:  2004-04

10.  The investigation and management of pancreatic exocrine insufficiency: A retrospective cohort study.

Authors:  Benjamin M Shandro; Jennifer Ritehnia; Joshua Chen; Rani Nagarajah; Andrew Poullis
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.